GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Ekso Bionics Holdings Inc (NAS:EKSO) » Definitions » ROE %

Ekso Bionics Holdings (Ekso Bionics Holdings) ROE % : -102.91% (As of Mar. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Ekso Bionics Holdings ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Ekso Bionics Holdings's annualized net income for the quarter that ended in Mar. 2024 was $-13.72 Mil. Ekso Bionics Holdings's average Total Stockholders Equity over the quarter that ended in Mar. 2024 was $13.33 Mil. Therefore, Ekso Bionics Holdings's annualized ROE % for the quarter that ended in Mar. 2024 was -102.91%.

The historical rank and industry rank for Ekso Bionics Holdings's ROE % or its related term are showing as below:

EKSO' s ROE % Range Over the Past 10 Years
Min: -306.02   Med: -216.21   Max: -46.88
Current: -87.88

During the past 12 years, Ekso Bionics Holdings's highest ROE % was -46.88%. The lowest was -306.02%. And the median was -216.21%.

EKSO's ROE % is ranked worse than
86.1% of 806 companies
in the Medical Devices & Instruments industry
Industry Median: 0.21 vs EKSO: -87.88

Ekso Bionics Holdings ROE % Historical Data

The historical data trend for Ekso Bionics Holdings's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ekso Bionics Holdings ROE % Chart

Ekso Bionics Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -254.74 -281.81 -46.88 -48.13 -79.89

Ekso Bionics Holdings Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -75.15 -86.57 -81.42 -92.28 -102.91

Competitive Comparison of Ekso Bionics Holdings's ROE %

For the Medical Instruments & Supplies subindustry, Ekso Bionics Holdings's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ekso Bionics Holdings's ROE % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Ekso Bionics Holdings's ROE % distribution charts can be found below:

* The bar in red indicates where Ekso Bionics Holdings's ROE % falls into.



Ekso Bionics Holdings ROE % Calculation

Ekso Bionics Holdings's annualized ROE % for the fiscal year that ended in Dec. 2023 is calculated as

ROE %=Net Income (A: Dec. 2023 )/( (Total Stockholders Equity (A: Dec. 2022 )+Total Stockholders Equity (A: Dec. 2023 ))/ count )
=-15.198/( (25.442+12.606)/ 2 )
=-15.198/19.024
=-79.89 %

Ekso Bionics Holdings's annualized ROE % for the quarter that ended in Mar. 2024 is calculated as

ROE %=Net Income (Q: Mar. 2024 )/( (Total Stockholders Equity (Q: Dec. 2023 )+Total Stockholders Equity (Q: Mar. 2024 ))/ count )
=-13.716/( (12.606+14.051)/ 2 )
=-13.716/13.3285
=-102.91 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Mar. 2024) net income data. ROE % is displayed in the 30-year financial page.


Ekso Bionics Holdings  (NAS:EKSO) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Mar. 2024 )
=Net Income/Total Stockholders Equity
=-13.716/13.3285
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-13.716 / 15.024)*(15.024 / 28.9375)*(28.9375 / 13.3285)
=Net Margin %*Asset Turnover*Equity Multiplier
=-91.29 %*0.5192*2.1711
=ROA %*Equity Multiplier
=-47.4 %*2.1711
=-102.91 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Mar. 2024 )
=Net Income/Total Stockholders Equity
=-13.716/13.3285
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-13.716 / -13.716) * (-13.716 / -13.024) * (-13.024 / 15.024) * (15.024 / 28.9375) * (28.9375 / 13.3285)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1 * 1.0531 * -86.69 % * 0.5192 * 2.1711
=-102.91 %

Note: The net income data used here is four times the quarterly (Mar. 2024) net income data. The Revenue data used here is four times the quarterly (Mar. 2024) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Ekso Bionics Holdings ROE % Related Terms

Thank you for viewing the detailed overview of Ekso Bionics Holdings's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Ekso Bionics Holdings (Ekso Bionics Holdings) Business Description

Traded in Other Exchanges
Address
101 Glacier Point, Suite A, San Rafael, CA, USA, 94901
Ekso Bionics Holdings Inc designs, develops and sells exoskeleton technology used in healthcare and industrial markets. The wearable exoskeletons are to be worn over clothes and controlled by a trained operator to augment human strength, endurance, and mobility. The company's segments are EksoHealth and EksoWorks. All of the company's operations are held in the United States. The EksoHealth segment which derives majority revenue designs, engineers, manufactures and sells exoskeletons for applications in the medical markets. The EksoWorks segment designs, engineers, manufactures, and markets exoskeleton devices to allow able-bodied users to perform difficult repetitive work for extended periods. The regions company operates in are the Americas, EMEA, and APAC.
Executives
Jerome Wong officer: Interim CFO C/O EKSO BIONICS HOLDINGS, INC., 1414 HARBOUR WAY SOUTH, SUITE 1201, RICHMOND CA 94804
Scott G. Davis officer: President & COO C/O EKSO BIONICS HOLDINGS, INC., 1414 HARBOUR WAY SOUTH, SUITE 1201, RICHMOND CA 94804
Steven Sherman director
Jason C Jones officer: VP of Product Development EKSO BIONICS HOLDINGS, INC., 1414 HARBOUR WAY SOUTH, SUITE 1201, RICHMOND CA 94804
John Glenn officer: Chief Financial Officer 7900 HOPYARD ROAD, APT 210, PLEASANTON CA 94577
Lathan Corinna director 140 KENDRICK STREET, NEEDHAM MA 02494
William R Shaw officer: See Remarks 1414 HARBOUR WAY SOUTH, SUITE 1201, C/O EKSO BIONICS HOLDINGS, INC., RICHMOND CA 94804
Rhonda A. Wallen director C/O EKSO BIONICS HOLDINGS, INC., 1414 HARBOUR WAY SOUTH, SUITE 1201, RICHMOND CA 94804
Mary Ann Cloyd director 184 LIBERTY CORNER ROAD, SUITE 302, WARREN NJ 07059
Combest Development (hong Kong) Ltd 10 percent owner ROOM 2210, CC WU BUILDING 302, HENNESSY ROAD, WAN CHAI, HONG KONG K3 999077
Jack Peurach director, officer: Chief Executive Officer 1414 HARBOUR WAY SOUTH, SUITE 1201, RICHMOND CA 94804
Thomas A Schreck director 10240 BUBB RD, CUPERTINO CA 95014
Puissance Capital Management Lp 10 percent owner 950 THIRD AVENUE, 25TH FLOOR, NEW YORK NY 10022
Christian Babini officer: VP of Sales, Americas C/O EKSO BIONICS HOLDINGS, INC., 1414 HARBOUR WAY SOUTH, SUITE 1, RICHMOND CA 94804
Puissance Cross-border Opportunities Ii Llc 10 percent owner C/O PUISSANCE CAPITAL FUND (GP) LLC, 950 THIRD AVENUE, NEW YORK NY 10022